STAT+: FDA approves new treatment from Biogen for rare form of ALS
The Food and Drug Administration on Tuesday granted conditional approval to a new treatment for a rare, genetic form of ALS — basing its decision for the first time on preliminary evidence that may also speed the development of future medicines for the fatal, neurodegenerative disease.
The new drug, called Qalsody, is made by Biogen.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: FDA approves new treatment from Biogen for rare form of ALS »
